IMR Press / CEOG / Volume 48 / Issue 2 / DOI: 10.31083/j.ceog.2021.02.2364
Open Access Original Research
Pregnancy and neonatal outcomes of hyperglycemia caused by atosiban administration during pregnancy
Show Less
1 Department of Obstetrics and Gynecology, Catholic University of Daegu, School of Medicine, 42472 Daegu, Korea
bjy2014@cu.ac.kr (Jin Young Bae)
These authors contributed equally.
Clin. Exp. Obstet. Gynecol. 2021, 48(2), 257–262; https://doi.org/10.31083/j.ceog.2021.02.2364
Submitted: 16 November 2020 | Revised: 13 December 2020 | Accepted: 31 December 2020 | Published: 15 April 2021
Copyright: © 2021 The Authors. Published by IMR Press.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

It is known that atosiban has fewer side effects than conventional tocolytics. In clinical practice, however, hyperglycemia can be commonly observed in mothers who have been administered atosiban. Therefore, we investigated whether intravenous atosiban injection actually causes hyperglycemia and how these changes affect newborns. From December 2015 to July 2018, a retrospective study was conducted on 96 mothers who were diagnosed with preterm labor and were administered atosiban at our institution. Maternal blood glucose was measured and compared before and during the administration of atosiban. The paired t-test, independent samples t-test, Chi-square test and Fisher’s exact test were performed using SPSS version 21.0. A statistically significant increase in fasting blood glucose levels was observed during the administration of atosiban, compared with random blood glucose levels before administration (110.7 mg/dL vs. 86.3 mg/dL). The mean postprandial blood glucose level during administration was 170.75 mg/dL. Gestational diabetes, twin pregnancy, preeclampsia, and polyhydramnios did not significantly affect the degree of blood glucose increase. Statistically significant hypoglycemia was observed after performing a neonatal blood test immediately after birth from mothers who used atosiban. The neonates from the group with elevated maternal blood glucose levels exceeding 20 mg/dL showed lower blood glucose levels. No serious side effects other than hypoglycemia were observed. Atosiban administration in pregnant women results in significantly elevated maternal blood glucose, which results in hypoglycemia in neonates after birth. Therefore, neonates from mothers who received atosiban require a blood glucose test and close monitoring after birth.

Keywords
Atosiban
Preterm labor
Maternal hyperglycemia
Neonatal hypoglycemia
Figures
Fig. 1.
Share
Back to top